Small, low-quality biotechs burdened with weak pipelines will often design and analyze clinical trials in a way that almost guarantees executives the ability to claim victory, even if the preponderance of the data produced say otherwise.
This is the dubious feat accomplished by ResTORbio (TORC) on Wednesday with a mid-stage clinical trial of a drug for respiratory tract infections.
About the Author Reprints
Once again, thank you for today’s analysis.
Bill